Loading stock data…
CAI
$18.47-0.53 (-2.79%)
Market ClosedLast close May 1
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Caris Life Sciences, Inc. in the Healthcare sector is trading at $18.47. The stock is currently near its 52-week low of $16.28, remaining 30.4% below its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why CAI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.47
Potential Upside
5%
Whystock Fair Value$19.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$29.69+60.8%
Range$21.00 – $38.00
Fundamentals
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.79B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.34%
Volume
Today's trading volume
1.95M
Recent News
3 Stocks Estimated To Be Trading Up To 43% Below Intrinsic Value
The United States market remained flat over the last week but has experienced a significant 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential gains while aligning with projected growth trends.
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings expected to grow by 16% per annum in the coming years. In this environment, identifying stocks that may be trading at an estimated discount can provide opportunities for investors seeking value amidst a generally rising market.
Caris Life Sciences, Inc. (CAI) Coverage Begins at Neutral as Piper Cites Need for Growth Acceleration
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Caris Life Sciences, Inc. is among the best biotech stocks. TheFly reported on April 10 that Piper Sandler began coverage of CAI with a Neutral rating and a $21 price target. The firm highlighted the company’s combination of strong […]
Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy Rating
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the most oversold healthcare stocks to invest in. Jefferies initiated coverage of Caris Life Sciences Inc. (NASDAQ:CAI) with a Buy rating on April 13, setting a $28 price target on the stock. The firm told investors that it sees “secular tailwinds” in the oncology diagnostics space from improving […]
April 2026's Estimated Undervalued Stocks For Savvy Investors
Over the last week, the United States market has seen a 4.4% increase, contributing to an impressive 32% rise over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer investors opportunities for growth by focusing on companies with strong fundamentals and attractive valuations relative to their peers.